Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2016-08-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
独立董事对公司当期关联方资金占用和对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding related party fund occupation and external guarantees during the reporting period. It references regulatory guidelines and company rules, and it is signed by independent directors. The content focuses on compliance and oversight rather than presenting full financial data or audit results. The document length is short (749 characters), and it is a standalone statement rather than a full audit report or annual report. This fits the category of an Audit Report / Information (AR), as it is a standalone audit-related opinion on specific matters (related party transactions and guarantees) without being a full annual report. H1 2016
2016-08-22 Chinese
第六届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jinling Pharmaceutical Co., Ltd. regarding the approval of the company's 2016 semi-annual report. It confirms that the report was reviewed and found to comply with legal and regulatory requirements, but the document itself is not the semi-annual report. The document length is short (771 characters) and it serves as an official announcement of the meeting and approval, not the full interim report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal disclosure related to the interim report but does not contain the report itself.
2016-08-22 Chinese
2016年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "金陵药业股份有限公司 2016 年半年度报告全文" which translates to "Jinling Pharmaceutical Co., Ltd. 2016 Semi-Annual Report Full Text." It contains detailed financial data, management discussion, business analysis, accounting data, and financial indicators for the first half of 2016 (reporting period: January 1, 2016 to June 30, 2016). The document includes comprehensive financial statements and analysis, which are characteristic of an Interim / Quarterly Report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is the report itself, not just an announcement or summary. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2016
2016-08-22 Chinese
第六届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 6th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on various board committee member appointments and the approval of the company's 2016 semi-annual report and its summary. The document explicitly states that the full semi-annual report and summary are available on external websites and newspapers, indicating this document itself is not the report but an announcement of board decisions and approvals. The focus is on board meeting resolutions, including committee changes and report approval, which aligns with Board/Management Information filings. The document length is short (1334 characters), and it does not contain the actual semi-annual financial data but references where to find it. Therefore, it is best classified as Board/Management Information (MANG).
2016-08-22 Chinese
2016年半年度财务报表附注
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial report containing extensive notes on accounting policies, company background, consolidation methods, financial instruments, asset valuation, and other accounting details. It references a half-year period ending June 30, 2016, indicating it is a semi-annual financial report. The length is substantial (15,000 characters), and it contains actual financial data and accounting explanations rather than just an announcement or summary. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes substantive financial data and analysis. There is no indication that this is an Annual Report (10-K), Audit Report (AR), or other categories such as Earnings Release or Investor Presentation. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2016
2016-08-22 Chinese
2016年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2016 年半年度报告摘要' which translates to '2016 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also includes management discussion and analysis of business operations and financial performance for the half-year period. The presence of comprehensive financial data and management analysis indicates this is a substantive interim financial report rather than a brief announcement or summary. The document length is 4518 characters, which is sufficient to contain detailed financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2016
2016-08-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.